Pfizer’s post-spinoff outlook is brighter

Study after study has shown that after an initial adjustment period of a few months, spinoffs tend to outperform groups of comparable stocks for several years. Still, in looking at two recent spinoff deals, we feel the spinoff of Pfizer’s generic drug business is more… Read More